$NRXS
Neuraxis, INC Stock $nrxs

$nrxs Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014832 Filed on April 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$611.5K	$531.5K	$2.460M
YoY Change	-5.34%	-13.31%
Cost Of Revenue	$73.46K	$72.35K	$303.4K
YoY Change	8.32%	-3.8%	2.12%
Gross Profit	$538.0K	$459.1K	$2.157M
YoY Change	-6.95%	-14.64%	-9.67%
Gross Profit Margin	87.99%	86.39%	87.67%
Selling, General & Admin	$2.691M	$2.085M	$8.652M
YoY Change	69.65%	44.49%	56.33%
% of Gross Profit	500.07%	454.04%	401.16%
Research & Development	$54.31K		$169.3K
YoY Change	-50.53%		-24.95%
% of Gross Profit	10.09%		7.85%
Depreciation & Amortization	$10.97K	$10.73K	$40.73K
YoY Change	44.55%	-11.18%	9.68%
% of Gross Profit	2.04%	2.34%	1.89%
Operating Expenses	$2.745M	$2.082M	$8.821M
YoY Change	61.87%	36.63%	53.15%
Operating Profit	-$2.207M	-$1.623M	-$6.664M
YoY Change	97.47%	64.59%	97.63%
Interest Expense	$80.70K	-$24.65K	-$280.6K
YoY Change	-58.55%	-88.98%	-85.44%
% of Operating Profit
Other Income/Expense, Net	-$710.9K	-$3.665M	-$7.682M
YoY Change	-36.42%	-406.4%	-1579.87%
Pretax Income	-$2.918M	-$5.313M	-$14.63M
YoY Change	30.25%	38882.47%	205.99%
Income Tax
% Of Pretax Income
Net Earnings	-$2.918M	-$5.313M	-$14.63M
YoY Change	30.51%	2474.03%	163.78%
Net Earnings / Revenue	-477.14%	-999.76%	-594.57%
Basic Earnings Per Share	-$0.42		-$4.50
Diluted Earnings Per Share	-$0.42	-$1.01	-$2.77
COMMON SHARES
Basic Shares Outstanding	6.595M shares	5.290M shares	3.252M shares
Diluted Shares Outstanding	6.921M shares		3.252M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.765M	$78.56K	$78.56K
YoY Change	3430.54%	-69.03%	-69.03%
Cash & Equivalents	$1.765M	$78.56K	$78.56K
Short-Term Investments
Other Short-Term Assets	$156.5K	$69.66K	$69.66K
YoY Change	682.25%	9442.47%	9442.47%
Inventory	$42.71K	$21.22K	$21.22K
Prepaid Expenses
Receivables	$147.1K	$73.17K	$73.17K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.112M	$242.6K	$242.6K
YoY Change	496.24%	-49.13%	-49.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$95.50K	$88.55K	$158.8K
YoY Change	12.0%	-53.24%	-16.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$521.8K	$266.9K	$266.9K
YoY Change	-55.99%	-73.41%	-73.41%
TOTAL ASSETS
Total Short-Term Assets	$2.112M	$242.6K	$242.6K
Total Long-Term Assets	$521.8K	$266.9K	$266.9K
Total Assets	$2.633M	$509.5K	$509.5K
YoY Change	71.03%	-65.59%	-65.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.118M	$1.204M	$1.204M
YoY Change	-54.13%	-24.36%	-24.36%
Accrued Expenses	$1.311M	$401.1K	$450.2K
YoY Change	11.62%	-53.76%	-48.1%
Deferred Revenue
YoY Change
Short-Term Debt	$4.767M	$148.1K	$0.00
YoY Change	217.82%	-48.3%
Long-Term Debt Due	$4.767M	$148.1K	$148.1K
YoY Change	1806.94%	-27.0%	-27.0%
Total Short-Term Liabilities	$7.594M	$1.886M	$1.886M
YoY Change	-33.57%	-72.98%	-72.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$297.8K	$27.07K	$27.07K
YoY Change	495.68%	-64.48%	-64.48%
Total Long-Term Liabilities	$297.8K	$27.07K	$27.07K
YoY Change	229.36%	-64.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.594M	$1.886M	$1.886M
Total Long-Term Liabilities	$297.8K	$27.07K	$27.07K
Total Liabilities	$7.892M	$1.913M	$1.913M
YoY Change	-31.51%	-72.89%	-72.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$53.60M	-$48.56M
YoY Change	39.79%	43.11%
Common Stock	$6.842K	$6.509K
YoY Change	248.55%	231.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.258M	-$1.403M	-$1.403M
YoY Change
Total Liabilities & Shareholders Equity	$2.633M	$509.5K	$509.5K
YoY Change	71.03%	-65.59%	-65.59%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.918M	-$5.313M	-$14.63M
YoY Change	30.51%	2474.03%	163.78%
Depreciation, Depletion And Amortization	$10.97K	$10.73K	$40.73K
YoY Change	44.55%	-11.18%	9.68%
Cash From Operating Activities	-$1.615M	-$2.634M	-$6.694M
YoY Change	156.37%	1129.05%	191.3%
INVESTING ACTIVITIES
Capital Expenditures	$8.690K	$11.78K	$30.78K
YoY Change		-76.35%	-49.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$8.690K	-$11.78K	-$71.78K
YoY Change		-76.35%	17.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.307M	1.961M	$6.591M
YoY Change	416.77%	284.43%	187.54%
NET CHANGE
Cash From Operating Activities	-1.615M	-2.634M	-$6.694M
Cash From Investing Activities	-8.690K	-11.78K	-$71.78K
Cash From Financing Activities	3.307M	1.961M	$6.591M
Net Change In Cash	1.684M	-685.1K	-$175.1K
YoY Change	16735.2%	-378.65%	160.78%
FREE CASH FLOW
Cash From Operating Activities	-$1.615M	-$2.634M	-$6.694M
Capital Expenditures	$8.690K	$11.78K	$30.78K
Free Cash Flow	-$1.624M	-$2.646M	-$6.725M
YoY Change	157.75%	901.69%	185.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Auditor Firm AuditorFirmId	89
CY2023Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023	NRXS	Stock Issued During Period Value Common Stock Issued Upon Preferred Stock Conversion StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion		usd
CY2022	NRXS	Noncash Interest Expense NoncashInterestExpense		usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	NRXS	Issuance Of Common Stock For Noncash Consideration IssuanceOfCommonStockForNoncashConsideration		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	NRXS	Deferred Offering Costs Paid DeferredOfferingCostsPaid		usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	NRXS	Prior Year Offering Costs Paid PriorYearOfferingCostsPaid		usd
CY2022	NRXS	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity		usd
CY2022	NRXS	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q4	us-gaap	Loans Payable LoansPayable		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2023Q4	NRXS	Underwriter Fees UnderwriterFees		usd
CY2023Q4	NRXS	Related Party Interest Payable Current RelatedPartyInterestPayableCurrent		usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount		usd
CY2023Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense		pure
CY2023	NRXS	Effective Income Tax Rate Reconciliation Nontaxable Income EffectiveIncomeTaxRateReconciliationNontaxableIncome		pure
CY2022	NRXS	Effective Income Tax Rate Reconciliation Nontaxable Income EffectiveIncomeTaxRateReconciliationNontaxableIncome		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q3	NRXS	Financing Charges FinancingCharges		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	0	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6594897	shares
CY2023	dei	Auditor Name AuditorName	Rosenberg Rich Baker Berman, P.A
CY2023	dei	Auditor Location AuditorLocation	Somerset, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78560	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	253699	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	73167	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	174399	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	21220	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	48133	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	69663	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	726	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	242610	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	476957	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	436626	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	405845	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	348074	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	317834	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88552	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88011	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	736736	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70263	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	101382	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	108073	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77558	usd
CY2023Q4	us-gaap	Assets Assets	509498	usd
CY2022Q4	us-gaap	Assets Assets	1480644	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1204219	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1592116	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	401088	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	834062	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	49127	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	33395	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	3327213	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	228342	usd
CY2023Q4	us-gaap	Deposits Deposits	74947	usd
CY2022Q4	us-gaap	Deposits Deposits	59174	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1735700	usd
CY2023Q4	NRXS	Warrant Liabilities WarrantLiabilities	8225	usd
CY2022Q4	NRXS	Warrant Liabilities WarrantLiabilities	2234384	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1885668	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6978058	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27071	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76199	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	27071	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	76199	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1912739	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7054257	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6508897	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6508897	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1963322	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1963322	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6509	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1963	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47148361	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28355230	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48558111	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33931428	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1403241	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5573613	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	509498	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1480644	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2684735	usd
CY2023	us-gaap	Gross Profit GrossProfit	2156704	usd
CY2023	us-gaap	Selling Expense SellingExpense	323569	usd
CY2022	us-gaap	Selling Expense SellingExpense	410883	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	169315	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	225610	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8328315	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5123420	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6664495	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3372238	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-844854	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-606049	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	198551	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	713989	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4881622	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	98935	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3649561	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	15133	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	11956	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	10355	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7962188	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1407823	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14626683	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4780061	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.50
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.50
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.77
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.77
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3252328	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3252328	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2003322	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2003322	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-825660	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27319	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4789	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4780061	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5573613	usd
CY2023	NRXS	Stock Issued During Period Value Common Stock Issued Upon Initial Public Offering StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering	4110677	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	9899483	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	750000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3720997	usd
CY2023	NRXS	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	315898	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14626683	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1403241	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14626683	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4780061	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4881622	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	98935	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40725	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37133	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25281	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	19505	usd
CY2023	NRXS	Noncash Lease Expense NoncashLeaseExpense	31119	usd
CY2022	NRXS	Noncash Lease Expense NoncashLeaseExpense	26593	usd
CY2023	NRXS	Noncash Interest Expense NoncashInterestExpense	260777	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27319	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3649561	usd
CY2023	NRXS	Issuance Of Common Stock For Noncash Consideration IssuanceOfCommonStockForNoncashConsideration	750000	usd
CY2023	NRXS	Finance Charges FinanceCharges	2772	usd
CY2022	NRXS	Finance Charges FinanceCharges	2322216	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	198551	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	713989	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-844854	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-606049	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-75951	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	78603	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-26913	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8953	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	68937	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-14944	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-387897	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1108326	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-294154	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	272425	usd
CY2023	NRXS	Increase Decrease In Customer Deposit IncreaseDecreaseInCustomerDeposit	15773	usd
CY2022	NRXS	Increase Decrease In Customer Deposit IncreaseDecreaseInCustomerDeposit	-10163	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-33396	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-27582	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6693978	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2298004	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30781	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1390	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	41000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	59815	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71781	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61205	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4847457	usd
CY2022	NRXS	Deferred Offering Costs Paid DeferredOfferingCostsPaid	736736	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	209097	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3533765	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	163214	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	159831	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	122000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5460000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3200000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	552000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	130000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6590620	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2292050	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-175139	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-67159	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	253699	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	320858	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	78560	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	253699	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	214562	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	202781	usd
CY2023	NRXS	Fair Value Of Warrant Liabilities Of Warrants From Convertible Notes FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes	2446502	usd
CY2022	NRXS	Fair Value Of Warrant Liabilities Of Warrants From Convertible Notes FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes	884118	usd
CY2023	NRXS	Fair Value Of Derivative Liabilities Of Conversion Feature From Convertible Notes FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes	2375378	usd
CY2022	NRXS	Fair Value Of Derivative Liabilities Of Conversion Feature From Convertible Notes FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes	1075098	usd
CY2023	NRXS	Prior Year Offering Costs Paid PriorYearOfferingCostsPaid	736736	usd
CY2023	NRXS	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	3720997	usd
CY2023	NRXS	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	1244	usd
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	1-for-2 reverse stock split
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1120000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zVDuaXrTLydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_862_zEz0MUIIsalf">Use of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for credit losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and equipment, and intellectual property. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	11993	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	31275	usd
CY2023	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	25281	usd
CY2022	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	64197	usd
CY2023Q4	us-gaap	Deposits Deposits	74947	usd
CY2022Q4	us-gaap	Deposits Deposits	59174	usd
CY2023Q4	NRXS	Inventory Expenses InventoryExpenses	25008	usd
CY2022Q4	NRXS	Inventory Expenses InventoryExpenses	10026	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	736736	usd
CY2023	us-gaap	Depreciation Depreciation	30240	usd
CY2022	us-gaap	Depreciation Depreciation	30920	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10485	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6213	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	192400	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	14900	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2190102	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3141752	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3596012	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14626683	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4780061	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-764893	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14626683	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5544954	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3252328	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3252328	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2003322	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2003322	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.50
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.50
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.77
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.77
CY2023	us-gaap	Revenues Revenues	2460049	usd
CY2022	us-gaap	Revenues Revenues	2684735	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zx8dJc3KAyve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zpHzMrGs96Kj">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the country.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables consist of unsecured amounts due from customers. As of December 31, 2023, accounts receivable from four customers with balances due in excess of <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHt7e9wt7Xlf" title="Risk percentage">10</span>% of total accounts receivable were approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1sgDO6lIT0f" title="Risk percentage">28</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOpddKc3C56k" title="Risk percentage">28</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztyL1NBusNqe" title="Risk percentage">17</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zn5iv9oSMJNe" title="Risk percentage">11</span>%, respectively. As of December 31, 2022, accounts receivable from three customers with balances due in excess of <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znlKTOeeo93f" title="Risk percentage">10</span>% of total accounts receivable was <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdf0D1ndQga7" title="Risk percentage">23</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJM0GLgbRMti" title="Risk percentage">15</span>%, and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFGIT1ta9kQ" title="Risk percentage">12</span>%, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below sets forth the Company’s customers that accounted for greater than <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_zSykzU9jrsr5" title="Risk percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_z8AOKkMvCXI4" title="Risk percentage">10</span></span>% of its revenues for the years ended December 31, 2023 and 2022, respectively.</span></p> <p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zK2CTGYbN3Sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zCjfnL75gsbi" style="display: none">Schedule of Customers Accounted Revenues</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Percentage of </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Percentage of </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: left"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: left"> </td><td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">Hospital A</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8DYsvEFfc62" style="width: 15%; font-weight: bold; text-align: right" title="Revenue">452,680</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOU9fy3LjPDl" title="Risk percentage">18</span>%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6VZ0fIq4lbg" style="width: 15%; text-align: right" title="Revenue">355,613</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGUAamau5Wg7" title="Risk percentage">13</span>%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Hospital B</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWtmDNKLOmZ8" style="font-weight: bold; text-align: right" title="Revenue">382,082</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxGlw7LXQHJh" title="Risk percentage">16</span>%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkkJm06MFCPb" style="text-align: right" title="Revenue">484,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8N4M2GNQ1Cg" title="Risk percentage">18</span>%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Hospital C</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoNS5KYKLCJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">274,581</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztiAPuHBO464" title="Risk percentage">11</span>%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAa3xtGHtem9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">554,325</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSTXRgI9fhP9" title="Risk percentage">21</span>%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPVkIhkG8i96" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">1,109,343</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAj2qbvuPNlj" title="Risk percentage">45</span>%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdpQH4bigBYb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">1,394,838</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zx1dh6xGR3J3" title="Risk percentage">52</span>%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8AE_zG8dOe1t08F5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company’s bank balances may exceed the FDIC limit of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_znBb1ljAlu7f" title="Cash, FDIC insured amount">250,000</span>; however, management does not feel that this has a material impact on the financial condition. At December 31, 2023 and 2022, the Company didn’t have any uninsured cash balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1403241	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	148062	usd
CY2023Q4	us-gaap	Cash Cash	78560	usd
CY2023Q4	NRXS	Working Capital Deficit WorkingCapitalDeficit	1643058	usd
CY2023Q4	NRXS	Allowance For Interest Receivable Current AllowanceForInterestReceivableCurrent	1154541	usd
CY2023Q4	NRXS	Interest And Service Fee Accrued InterestAndServiceFeeAccrued	66648	usd
CY2023	us-gaap	Interest Paid InterestPaid	37103	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	58051	usd
CY2022Q4	NRXS	Interest And Service Fee Accrued InterestAndServiceFeeAccrued	98290	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	436626	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	405845	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	348074	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	317834	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88552	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88011	usd
CY2023	us-gaap	Depreciation Depreciation	30240	usd
CY2022	us-gaap	Depreciation Depreciation	30920	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	133278	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	92278	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	25205	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14720	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	108073	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77558	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10485	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6213	usd
CY2023Q4	NRXS	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	333477	usd
CY2022Q4	NRXS	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	539558	usd
CY2022Q4	NRXS	Underwriter Fees UnderwriterFees	88259	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	66648	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	173826	usd
CY2022Q4	NRXS	Related Party Interest Payable Current RelatedPartyInterestPayableCurrent	31642	usd
CY2023Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	963	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	777	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	401088	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	834062	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3555556	usd
CY2022Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	355556	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2841658	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	130000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	228342	usd
CY2023Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2375378	usd
CY2023Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	2446502	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	962223	usd
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	Two of the leases in Versailles started January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments for these leases are $550 and $1,600 with a 3% per annum increase starting with the optional five-year term. The lease in Carmel started March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment started at $1,472 with an annual increase of approximately 2.7%. On December 16, 2020, the Company entered into an amendment of the Carmel lease that extended the initial term by two years.
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	49051	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	47571	usd
CY2023	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	0.80	pure
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3000000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.085	pure
CY2023Q4	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	200000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70263	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	101382	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	49127	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33395	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27071	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76199	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	76198	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	109594	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.150	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.150	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	27072	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	22316	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	26810	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	76198	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	76198	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6508897	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1963322	shares
CY2023Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1244228	shares
CY2023Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	506637	shares
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	2-for-1 reverse stock split
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	2-for-1 reverse stock split
CY2019Q3	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	Since the fair value was greater than the warrant price of $0.01 per share the holder elected to receive the number of shares equal to 40,000 times the difference between the fair market value and the exercise price divided by the fair market value, resulting in 39,924.
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	2-for-1
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1822358	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1120000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M8D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M8D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1319394	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y8M8D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.94
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03	pure
CY2023	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	6980	usd
CY2022	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	17183	usd
CY2022Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	417390	usd
CY2023Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	417390	usd
CY2019Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5000000	usd
CY2022Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	75000	usd
CY2023	us-gaap	Health Care Organization Stop Loss Insurance Premium Expense HealthCareOrganizationStopLossInsurancePremiumExpense	255715	usd
CY2022	us-gaap	Health Care Organization Stop Loss Insurance Premium Expense HealthCareOrganizationStopLossInsurancePremiumExpense	196929	usd
CY2023	NRXS	Health Care Organization Stop Loss Insurance Premium Percentage HealthCareOrganizationStopLossInsurancePremiumPercentage	0.485	pure
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	169315	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	225466	usd
CY2023Q4	NRXS	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	-15175	usd
CY2022Q4	NRXS	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	-16098	usd
CY2023Q4	NRXS	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	-14195	usd
CY2022Q4	NRXS	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	-19290	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	718893	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	767861	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3653490	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3653490	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6573406	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3309340	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10916419	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7695303	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.047	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.259	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.257	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3221116	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1136470	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	28238445	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	25543000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	3000000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.085	pure
	NRXS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	3721007	usd
CY2023Q3	NRXS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	3721007	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	761249	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	132382	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	34530	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38693	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	966854	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	420586	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	340260	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80326	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	78043	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	110695	usd
CY2023Q3	us-gaap	Assets Assets	1235918	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	566649	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	280063	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45194	usd
CY2023Q3	us-gaap	Deposits Deposits	68972	usd
CY2023Q3	NRXS	Share Liabilities Current ShareLiabilitiesCurrent	934256	usd
CY2023Q3	NRXS	Warrant Liabilities WarrantLiabilities	168269	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2257652	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39353	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2297005	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	5149	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45899577	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46965813	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1061087	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1235918	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	477460	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1928590	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	67287	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	231000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	410173	usd
	us-gaap	Gross Profit GrossProfit	1697590	usd
CY2023Q3	us-gaap	Selling Expense SellingExpense	64210	usd
	us-gaap	Selling Expense SellingExpense	250933	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44950	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	171536	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3323352	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6316411	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3022339	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5041290	usd
	NRXS	Financing Charges FinancingCharges	2772	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	102628	usd
	us-gaap	Interest Expense InterestExpense	453869	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	2103	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	2103	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-592853	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-791610	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6394	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	198551	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1331030	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4881622	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4779069	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3649571	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	9931	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	11483	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1578	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9008	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5603024	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7993095	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-8625363	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13034385	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13034385	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4881622	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30290	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6380	usd
	NRXS	Noncash Lease Expense NoncashLeaseExpense	23339	usd
	NRXS	Noncash Interest Expense NoncashInterestExpense	260777	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3649571	usd
	NRXS	Issuance Of Common Stock For Noncash Consideration IssuanceOfCommonStockForNoncashConsideration	2550000	usd
	NRXS	Finance Charges FinanceCharges	2772	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	198551	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-791610	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-35637	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-13603	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	37967	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1025467	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-415181	usd
	NRXS	Increase Decrease In Customer Deposit IncreaseDecreaseInCustomerDeposit	9798	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-25047	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4064419	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14741	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	41000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55741	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5464642	usd
	NRXS	Offering Costs In Advance Of Sale Of Common Stock OfferingCostsInAdvanceOfSaleOfCommonStock	-2417185	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3487578	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	159831	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4908000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4627710	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	507550	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	253699	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	761249	usd

Files In Submission

Name	View Source	Status
0001493152-24-014832-index-headers.html	Edgar Link	pending
0001493152-24-014832-index.html	Edgar Link	pending
0001493152-24-014832.txt	Edgar Link	pending
0001493152-24-014832-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
form10-k_009.jpg	Edgar Link	pending
form10-k_010.jpg	Edgar Link	pending
form10-k_011.jpg	Edgar Link	pending
form10-k_012.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nrxs-20231231.xsd	Edgar Link	pending
pg_001.jpg	Edgar Link	pending
pg_002.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
nrxs-20231231_cal.xml	Edgar Link	unprocessable
nrxs-20231231_def.xml	Edgar Link	unprocessable
nrxs-20231231_lab.xml	Edgar Link	unprocessable
nrxs-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NRXS
Neuraxis, INC Stock $nrxs

2024 Q2 Form 10-K Financial Statement

#000149315224014832 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NRXS Neuraxis, INC Stock $nrxs

2024 Q2 Form 10-K Financial Statement

#000149315224014832 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NRXS
Neuraxis, INC Stock $nrxs